China Medical Device Risk Classifications: How NMPA Device Class Determines Registration Pathways

China medical device risk classifications are the starting point for every regulatory decision a manufacturer makes when entering the China market. Assigned before a registration dossier is submitted, device class determines how the NMPA evaluates a product — shaping approval pathways, clinical evidence expectations, review timelines, and long-term compliance obligations throughout the device's lifecycle.

For foreign manufacturers, confirming the correct classification early is essential to avoiding delays, rework, and unexpected regulatory escalation.

Continue below for the full explainer, or get in touch with Cisema for support in confirming your China medical device classification and aligning your NMPA registration strategy.

What Is China Medical Device Classification Under NMPA Regulations?

China regulates medical devices through a risk-based classification system administered by the National Medical Products Administration (NMPA). This system is formally established under the Classification Rules for Medical Devices, which define how products are assigned regulatory classes based on their intended use, technical characteristics, and potential risk to patients, users, or public health. As device risk increases, the level of regulatory oversight, documentation, and post-market responsibility increases accordingly.

For overseas manufacturers, the assigned medical device class determines:

• Whether the product follows medical device filing or full NMPA registration
• The scope of China medical device type testing
• Clinical evaluation or clinical trial requirements
• Review timelines for medical device approval in China
• Post-market surveillance and renewal obligations

China applies this framework separately to general medical devices and in vitro diagnostic medical devices (IVDs). While the underlying risk principles are aligned, the classification logic and catalogs differ. For a detailed explanation of how this framework applies specifically to diagnostics, read our article “China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways.”

China Medical Device Risk Classes Explained (Class I – Class III)

China divides medical devices into 3 NMPA medical device classes: Class I, Class II, and Class III. Each class represents a step increase in regulatory scrutiny, documentation depth, and lifecycle compliance responsibility.

Before reviewing each class in detail, it is important to clarify how China formally assigns classification through its official catalog system.

What is the China Medical Device Classification Catalog?

China assigns medical device classifications through the Medical Device Classification Catalog, which operates under the Classification Rules for Medical Devices. The catalog is a legally binding taxonomy that groups devices by intended use, technical characteristics, and risk level. As of 2026, it covers 44 product categories across Class I, Class II, and Class III and functions as an annex to the regulations, translating high-level classification principles into enforceable NMPA-recognized categories.

Key points foreign manufacturers often overlook include:

• The catalog classifies devices by product category, not individual models
• Products with similar technology may fall into different classes depending on claims and use scenarios
• Accessories and software may carry independent classifications

Misreading or oversimplifying catalog entries is one of the most common causes of downstream reclassification during NMPA review.

Class I Medical Devices in China (Low-Risk Medical Devices)

Class I medical devices are low-risk products with established safety profiles and minimal impact on patient health if malfunction occurs. These devices are generally non-invasive or intended for passive, temporary (up to 24-hour) use and do not support critical physiological functions.

Regulatory characteristics include:

• Medical device filing rather than full NMPA approval
• No clinical trial requirements
• Focus on basic safety and quality system documentation
• A total of 5 working days for review

Typical Class I medical device examples include:

• Stethoscopes
• Bandages
• Wheelchairs
• Walking aids
• Compression hosiery

For foreign manufacturers, Class I devices often represent the fastest and least resource-intensive route to China medical device market entry, provided classification is correctly confirmed.

Class II Medical Devices in China (Moderate-Risk Medical Devices)

Class II medical devices present moderate risk due to closer interaction with the human body or reliance on electrical, monitoring, or diagnostic functions.

China medical device registration at this level requires:

• Mandatory China medical device type testing
• Detailed technical documentation
• Evidence of safety and performance consistency
• 60 working days of technical review

Representative Class II medical device examples include:

• Electrocardiographs (ECG)
• Transcutaneous electrical neuromuscular stimulators (TENS)
• Hearing aids
• Electronic blood pressure monitors
• Urinary catheters

Class III Medical Devices in China (High-Risk Medical Devices)

Class III medical devices pose significant risk and often support life-sustaining functions or advanced diagnostics implantable, life-sustaining, or critical to patient survival. Failure at this level can result in serious patient harm.

Regulatory expectations typically include:

• Comprehensive clinical evaluation reports
• Potential local clinical trials in China
• Extended NMPA technical review timelines – 90 working days

Examples of Class III medical devices include:

• Contact lens care solutions
• Diagnostic X-ray machines
• Automated external defibrillators (AEDs)
• Insulin pens
• Prosthetic joints

For foreign companies, Class III medical device classification directly affects China launch feasibility, cost, and time-to-market. At this level, NMPA approval should be approached as a long-term regulatory commitment.

Common China Medical Device Classification Mistakes and How to Avoid Them

Many delays in China medical device registration have little to do with the product’s actual risk. More often, they stem from early classification assumptions that go unchallenged until the NMPA review process exposes them. These missteps can lead to approval delays, unexpected evidence requests, and costly rework — especially for foreign manufacturers navigating China’s system for the first time.

Understanding where companies typically go wrong makes it easier to avoid these pitfalls before they disrupt a registration plan.

Misinterpreting Classification Drivers: Intended Use, Claims, and Features

A common misconception is that medical device classification in China is determined by product name or by how closely a device resembles something already listed in the NMPA catalog. In reality, classification is driven by intended use, clinical function, duration of contact, and risk exposure.

Additional features (such as software algorithms, connectivity, home-use claims, pediatric indications, or decision-support functions) can elevate a device into a higher risk class even when the core technology appears unchanged.

To reduce the risk of reclassification during review, manufacturers should complete a structured intended-use and claims assessment early. Aligning labeling, instructions for use, software logic, and accessory configurations before submission helps avoid surprises later in the process

Assuming Global Approvals and Budgets Translate Directly to China

Many foreign manufacturers expect China medical device classification and approval requirements to align with EU MDR or FDA frameworks. While global approvals are valuable reference points, China applies its own regulatory logic, testing standards, and clinical evaluation expectations.

This assumption often leads to underestimated timelines and budgets, particularly for Class II and Class III devices, where China-specific testing or additional clinical evidence may be required. Reassessing classification independently under China regulations and planning for multiple regulatory scenarios helps protect launch timelines and internal commitments.

Treating Classification as a One-Time Task Instead of a Lifecycle Commitment

Classification in China does not end with initial approval. The assigned device class determines how post-market changes are handled, including design updates, supplier changes, software revisions, labeling updates, renewals, and portfolio expansions.

Manufacturers that treat classification as a one-off administrative step often encounter compliance challenges later, especially during post-market change submissions or renewals. Establishing post-approval change management procedures aligned with the approved device class before registration is completed supports long-term compliance and smoother portfolio management in China.

Key Takeaways on China Medical Device Classification

China medical device risk classification underpins every stage of NMPA review, from selecting the correct registration pathway to managing post-market changes and renewals. When classification is inaccurate or weakly justified, the consequences often surface later as review delays, additional evidence requests, and avoidable regulatory cost.

For foreign manufacturers, confirming the correct classification early is one of the most effective ways to reduce regulatory uncertainty. When classification is validated upfront and registration planning reflects China-specific requirements, approval timelines become more predictable and lifecycle compliance easier to manage.

With more than 20 years of on-the-ground regulatory experience in China, Cisema supports foreign manufacturers in confirming medical device classification, structuring NMPA registration pathways, and managing ongoing compliance across the product lifecycle. For medical device companies seeking a predictable and defensible route to the China market, get in touch with Cisema today to move forward with clarity and confidence.

Further Information

• Explore Cisema’s Medical Device Consulting and Registration Services in China, including support for NMPA classification confirmation, registration planning, and lifecycle compliance.
• Explore Cisema’s Medical Device Registration Services Across Asia Pacific, covering regulatory approval in Hong Kong, Taiwan, and Southeast Asia.

References

• Read the Rules for Classification of Medical Devices (Decree No. 15 of the China Food and Drug Administration) (English)
• Refer to the Medical Device Classification Catalog (医疗器械分类目录) issued by the National Medical Products Administration (Chinese)
• Refer to the In Vitro Diagnostic Reagent Classification Catalog (体外诊断试剂分类目录) issued by the National Medical Products Administration (Chinese)
• Refer to the Classification Rules for In Vitro Diagnostic Reagents (体外诊断试剂分类规则) issued by the National Medical Products Administration (Chinese)

Frequently Asked Questions About China Medical Device Risk Classification

How Do I Determine the Correct Medical Device Class in China?‍

Determine China medical device classification by comparing the product’s intended use, invasiveness, duration of patient contact, and risk to human health against the NMPA Medical Device Classification Catalog. Innovative, software-enabled, or multi-functional devices often do not fit cleanly within a single catalog entry. In these cases, classification must be supported by technical comparison and clear regulatory justification. To avoid misclassification that can delay approval, foreign manufacturers often pursue formal classification confirmation or expert review before finalizing their NMPA registration strategy

What Happens If My Medical Device Is Misclassified in China?‍

Misclassification is a leading cause of NMPA review suspension or rejection. If a product is classified at too low a risk level, regulators may halt the review and require resubmission under a higher class.
Correcting classification after submission can add several months to the China medical device approval process, making early validation a critical risk-control step.

Does a Higher Medical Device Class Mean Longer Approval Time in China?‍

Yes. As medical device class increases, regulatory scrutiny, documentation depth, and review timelines also increase.

Are Clinical Trials Always Required for Class III Medical Devices?‍

Not always, but clinical evaluation is mandatory, and local clinical trials are often required for Class III medical, especially if the product is novel or lacks sufficient comparable clinical data. The final determination depends on product risk, existing clinical evidence, and alignment with Chinese regulatory standards.

Are IVD Medical Devices Classified Differently from Other Medical Devices in China?‍

Yes. IVD medical devices follow a separate China risk classification system due to their diagnostic and public health impact. Manufacturers offering both medical devices and IVDs must assess classification independently under each regulatory framework, even when products are technically linked.

For more information on IVD risk classification, read our article “China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways”